17159-82-9

Basic information

• Product Name: 1,4-dioxaspiro[4.5]decan-8-ylmethanol
• Synonyms: 1,4-dioxaspiro[4.5]decan-8-ylmethanol;1,4-Dioxaspiro[4.5]decane-8-Methanol
• CAS NO: 17159-82-9
• Molecular Formula: C₉H₁₆O₃
• Molecular Weight: 172.22154
• Mol File: 17159-82-9.mol
• Article Data: 51

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 1,4-dioxaspiro[4.5]decan-8-ylmethanol(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-dioxaspiro[4.5]decan-8-ylmethanol(17159-82-9)
• EPA Substance Registry System: 1,4-dioxaspiro[4.5]decan-8-ylmethanol(17159-82-9)

Safety Data

• Hazardous Substances Data: 17159-82-9(Hazardous Substances Data)

Usage

General Description

1,4-dioxaspiro[4.5]decan-8-ylmethanol is a chemical compound with the molecular formula C10H18O3. It is a white crystalline solid with a faint odor, and it is soluble in water and most organic solvents. 1,4-dioxaspiro[4.5]decan-8-ylmethanol is commonly used as a synthetic building block in organic and medicinal chemistry, particularly in the synthesis of pharmaceuticals and agrochemicals. It is also utilized in the production of fragrances and flavors, as well as in the creation of novel materials and bioactive compounds. 1,4-dioxaspiro[4.5]decan-8-ylmethanol has a wide range of applications due to its reactivity and versatility, making it an important component in various industries.

Upstream product

• 26845-47-6 methyl 1,4-dioxaspiro[4.5]decane-8-carboxylate 
• 38580-68-6 4-hydroxymethyl-cyclohexanone 
• 107-21-1 ethylene glycol 
• 1489-97-0 ethyl 1,4-dioxaspiro[4.5]decane-8-carboxylate 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 3289-28-9 ethyl cyclohexanecarboxylate 
• 93245-98-8 1,4-dioxaspiro[4.5]decane-8-carbaldehyde 
• 3685-22-1 4-hydroxycyclohexanecarboxylic acid 
• 6297-22-9 4-carbomethoxycyclohexanone 
• 183-97-1 1,4,9,12-Tetraoxa-dispiro[4.2.4.2]tetradecane 
• 59691-19-9 1-Methoxy-4-(hydroxymethyl)-1,4-cyclohexadiene 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 3618-03-9 methyl 4-hydroxycyclohexanecarboxylate 

Downstream Products

• 74286-87-6 8-(bromomethyl)-1,4-dioxaspiro<4,5>decane 
• 132452-42-7 8-((benzyloxy)methyl)-1,4-dioxaspiro[4.5]decane 
• 93245-98-8 1,4-dioxaspiro[4.5]decane-8-carbaldehyde 
• 599174-24-0 8-(4-methoxy-benzyloxymethyl)-1,4-dioxa-spiro[4.5]decane 
• 38580-68-6 4-hydroxymethyl-cyclohexanone 
• 599174-28-4 C₃₂H₄₂N₄O₇S 
• 625114-56-9 8-iodomethyl-1,4-dioxa-spiro[4.5]decane 
• 58230-40-3 9-benzoyl-3-hydroxymethyl-1,2,3,4-tetrahydrocarbazole 
• 1403676-95-8 tert-butyl 4-(4-((2-fluoro-4-(methylsulfonyl)phenoxy)methyl)-2-oxocyclohexyl)piperazine-1-carboxylate 
• 1403676-73-2 8-((2-fluoro-4-(methylsulfonyl)phenoxy)methyl)-1,4-dioxaspiro[4.5]decane 

Relevant articles and documents

3-(dimethylaminomethyl) cyclohex-4-alcohol derivative as well as preparation method and pharmaceutical application thereof

The invention belongs to the field of pharmacy, and relates to a 3-(dimethylaminomethyl) cyclohex-4-alcohol derivative with a general formula (I) or a salt thereof and a preparation method, and relates to an application of the compound in treatment of opioid receptor mediated diseases. The present invention provides a pharmaceutically acceptable solvate or hydrate of a compound of formula (I), and also provides a pharmaceutical composition comprising: a compound of formula (I) or a pharmaceutically acceptable salt, solvate or hydrate thereof; and a pharmaceutically acceptable carrier. The medicine prepared from the compound can be used for treating or improving diseases related to an opioid receptor; wherein the diseases can be selected from but not limited to pain, gastrointestinal diseases and depression.

LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT

PROBLEM TO BE SOLVED: To improve Δn of a liquid crystal compound. SOLUTION: One aspect of the present invention is a liquid crystal compound represented by general formula (i) [where Ri1 is a C1 to 15 alkyl group or the like, Ri2 is

Design, synthesis and SAR study of bridged tricyclic pyrimidinone carboxamides as HIV-1 integrase inhibitors

The design, synthesis and structure-activity relationships associated with a series of bridged tricyclic pyrimidinone carboxamides as potent inhibitors of HIV-1 integrase strand transfer are described. Structural modifications to these molecules were made in order to examine the effect on potency towards wild-type and clinically-relevant resistant viruses. The [3.2.2]-bridged tricyclic system was identified as an advantageous chemotype, with representatives exhibiting excellent antiviral activity against both wild-type viruses and the G140S/Q148H resistant virus that arises in response to therapy with raltegravir and elvitegravir.